CRNX Crinetics Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CRNX matters now
Crinetics Pharmaceuticals, Inc. (CRNX) is a US stock in Healthcare. The latest InvestLog snapshot shows $83.58 with -0.05% on the session and $8.85B in market capitalization; recent performance reads 1-month +2.66% and YTD -22.94%.
The latest financial table shown here is Q1 2026, with revenue of $10.7M, net income of $-127.8M, and EPS of $-1.23. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.1%.
The latest indexable market news headline is "Why This Pharmaceutical Stock Jumped Close to 100% This Week" from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Buy with a median target of $84.00; recent insider activity includes Okey Stephanie filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.92
P/S
209.32
EV/EBITDA
-7.55
DCF Value
$-7.50
FCF Yield
-11.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.9%
Operating Margin
-3020.3%
Net Margin
-2747.2%
ROE
-44.0%
ROA
-35.4%
ROIC
-40.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.7M | $-127.8M | $-1.23 |
| Q4 2025 | $6.2M | $-122.8M | $-1.30 |
| FY 2025 | $7.7M | $-465.3M | $-4.95 |
| Q3 2025 | $143.0K | $-130.1M | $-1.38 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$85.14
Target (Median)
$84.00
Target Range
$67.00 - $105.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.24
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.